Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

Julie Rosenthal, MD, MS, discusses the future direction of research into treating age-related macular degeneration.

The company is set to release topline results from its Phase 3 superiority trial of Axpaxli in wet AMD on Tuesday. ・Ocular previously said that positive results could support a New Drug Application ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...

An Ocular Therapeutix drug developed for the wet form of age-related macular degeneration was better at helping patients maintain vision compared to a blockbuster Regeneron Pharmaceuticals drug that ...

Researchers think they know why eye injections for “wet” AMD sometimes fail The eye injections actually increase a protein linked to new blood vessel growth An experimental drug reduced levels of ...

Age-Related Macular Degeneration (AMD) is the biggest cause of sight loss in the UK, affecting around 700,000 people. As February is AMD Awareness Month, Optegra Eye Clinic West London is spotlighting ...

Newmedica Worcester highlights AMD Awareness Month, urging early detection of age-related macular degeneration—the UK’s leading cause of ...

Researchers at Science Tokyo developed an mRNA vaccine that suppressed abnormal retinal blood vessel growth in mouse models. The vaccine can be administered intramuscularly and showed effectiveness ...